Acute lymphoblastic leukemia is the most prevalent form of leukemia in children and adolescents. Despite high survival rates due to advanced treatments, these therapies often result in significant treatment-related adverse effects. This scoping review explores dietary supplementation strategies for managing these adverse effects in pediatric leukemia patients. Twelve studies were included, involving participants aged between 0.8 and 21 years, all undergoing chemotherapy at various treatment phases. Chemotherapy-related adverse effects identified in this review included gastrointestinal symptoms, cardiometabolic risk factors, hepatotoxicity, osteopathies, neuro-psychiatric effects, hematological disorders, and changes in body composition. The dietary supplements evaluated for managing these effects were probiotics, ginger, glutamine, omega-3, vitamin D, calcium, potassium, honey, chamomile, and medium-chain triglyceride. Most of these supplements showed promising outcomes in reducing or preventing adverse effects. However, there is a demand for more rigorous clinical trials with larger sample sizes and standardized protocols to validate the efficacy of these interventions. Further research to identify optimal dosages, better understand long-term effects, and develop evidence-based guidelines for the use of dietary supplements in managing treatment-related adverse effects in children and adolescents with leukemia is needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/01635581.2024.2435079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase 1 study of AYP-101 (soybean phosphatidylcholine): safety, pharmacokinetics, and lipid profile effects for reducing submental fat.
Lipids Health Dis
December 2024
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, 13620, Republic of Korea.
Background: Excessive submental fat under the chin is a known aesthetic concern because of its negative impact on facial appearance and psychological well-being. AYP-101 is a newly developed injectable agent containing 93% soybean phosphatidylcholine (SPC) designed to reduce submental fat. We conducted a phase 1 study to evaluate the safety, pharmacokinetic (PK), and lipid profile effects of AYP-101.
View Article and Find Full Text PDFChanging the culture: increasing captured intraoperative anaesthesia-related safety events through targeted interventions.
BMJ Open Qual
December 2024
Anesthesiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Background: There is an under-reporting of anaesthesia-related safety events. Incident-capturing systems (ICSs) are essential for patient safety monitoring, identifying risks and ongoing opportunities for improvement. After a literature review and assessment of our current ICSs, we concluded that our institution lacked a reliable anaesthesia-specific ICS system, leading to under-reporting of anaesthesia-related safety events.
View Article and Find Full Text PDFPrimary components of MCT ketogenic diet are detrimental to bone loss associated with accelerated aging and age-related neurotoxicity in mice.
Bone
December 2024
Neurobehavioral Pharmacology Laboratory, Department of Pharmacology, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India. Electronic address:
Medium chained triglycerides (MCT) ketogenic diet is being extensively investigated for its neuroprotective effects against adverse effects associated with aging and neurodegenerative disorders. Aging is a common risk factor for the development of both osteoporosis and neurological disorders. Hence, suppression of aging and age-related neurodegeneration might contribute to delaying skeletal aging.
View Article and Find Full Text PDFEffects of MAO‑B Inhibitors in life quality of Parkinson's disease patients: a Systematic Review and Meta‑Analysis.
Behav Brain Res
December 2024
Department of Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China; Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-sen University, Sun Yat-Sen University, Shenzhen, China. Electronic address:
Introduction: Monoamine oxidase-B (MAO-B) inhibitors, as an add-on therapy to levodopa, are widely used in Parkinson's disease (PD). The effects of MAO-B inhibitors on quality of life remain unclear, and the aim of this systematic review and meta-analysis was to assess the efficacy and safety of MAO-B inhibitors on quality of life in different domains.
Methods: We searched PubMed, Embass, and Cochrane Library databases for randomized controlled trials of PD patients who were administered MAO-B inhibitors.
Self-assembled natural triterpenoids for the delivery of cyclin-dependent kinase 4/6 inhibitors to enhance cancer chemoimmunotherapy.
J Control Release
December 2024
Key Laboratory of Natural Medicine Innovation and Transformation, Henan University, Kaifeng 475000, PR China; State Key Laboratory of Antiviral Drugs, Henan University, Kaifeng 475000, PR China; Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, PR China. Electronic address:
Immunogenic cell death (ICD) has recently emerged as a promising strategy in reinforcing anti-PD-L1 blockade immunotherapy of triple-negative breast cancer (TNBC). The CDK4/6 inhibitor palbociclib (PAL), as a clinical star medicine targeting the cell cycle machinery, is an ideal candidate for fabricating a highly efficient ICD inducer for TNBC chemoimmunotherapy. However, the frequently observed chemoresistance and clinical adverse effects, as well as significant antagonistic effects when co-administered with certain chemotherapeutics, have seriously restricted the efficiency of PAL and the feasibility of combination strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!